Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021:217:197-207.
doi: 10.1007/978-3-030-57362-1_9.

Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease

Richard F Ambinder  1
Affiliations

Epstein-Barr Virus-Associated Post-transplant Lymphoproliferative Disease

Richard F Ambinder. Recent Results Cancer Res. 2021.

Abstract

Epstein-Barr virus (EBV) is associated with a variety of malignancies including post-transplant lymphoproliferative disease (PTLD). These include B and T cell lymphomas, epithelial, and mesenchymal tumors. The virus is ubiquitous, transmitted in saliva, and not usually associated with the development of malignancy. PTLD is usually associated with EBV when it occurs soon after the transplant. Measurement of viral DNA in blood, especially plasma, may be useful in the diagnosis of PTLD. Treatment approaches include withdrawal of immunosuppression, monoclonal antibodies or antibody conjugates, cytotoxic chemotherapy, and a variety of virus-specific treatments such as adoptive cellular therapy with EBV-specific T cells. Approaches to prevention include selection of immunosuppressive regimens that minimize the risk. In the future, EBV vaccines may be available for potential transplant recipients.

Keywords: Cancer; Epstein–Barr virus (EBV); Hematologic cell transplant; Lymphoma; Post-transplant lymphoproliferative diseases (PTLD); Solid organ transplant.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J, Yu YW, Han DS, Li XJ, Zhang YQ, Cai HL, Xiao YH, Zheng X. Hu J, et al. Front Immunol. 2023 Sep 15;14:1244534. doi: 10.3389/fimmu.2023.1244534. eCollection 2023. Front Immunol. 2023. PMID: 37781359 Free PMC article.
  • Increased EBV DNAemia after Anti-SARS-CoV-2 Vaccination in Solid Organ Transplants.
    Musialik J, Kolonko A, Więcek A. Musialik J, et al. Vaccines (Basel). 2022 Jun 22;10(7):992. doi: 10.3390/vaccines10070992. Vaccines (Basel). 2022. PMID: 35891156 Free PMC article.
  • The EHA Research Roadmap: Malignant Lymphoid Diseases.
    Dreyling M, André M, Gökbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Maria Ribera J, Zweegman S, Aurer I, Bödör C, Burkhardt B, Buske C, Dollores Caballero M, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Grønbæk K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman-Parker J, Le Gouill S, Lenz G, Leppä S, Lopez-Guillermo A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trümper LH, Salles G. Dreyling M, et al. Hemasphere. 2022 May 19;6(6):e726. doi: 10.1097/HS9.0000000000000726. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35620592 Free PMC article. No abstract available.

MeSH terms